论文部分内容阅读
目的:观察盐酸坦索罗辛治疗BPH的临床疗效。方法:对22例患者均予盐酸坦索罗辛0.2 mg,口服,QN,连服6周。观察治疗前、后的国际前列腺症状评分(IPSS)、生活质量评分(QOL)、膀胱剩余尿(RV)及最大尿流率(Q_(max))等指标。结果:与治疗前相比,患者的IPSS评分明显下降(12.4±3.5 vs 22.4±6.8),QOL、Q_(max)、RV等亦得以明显改善。结论:对于前列腺体积中、轻度增大者,单用哈乐即可达到理想疗效,从而降低患者经济负担,提高长期用药的依从性。
Objective: To observe the clinical efficacy of tamsulosin hydrochloride in the treatment of BPH. Methods: All the patients were given tamsulosin 0.2 mg orally and QN for 6 weeks. The scores of IPSS, QOL, RV and Qmax before and after treatment were observed. Results: Compared with those before treatment, the patients’ IPSS scores decreased significantly (12.4 ± 3.5 vs 22.4 ± 6.8), QOL, Q max, RV and so on were also significantly improved. CONCLUSION: For patients with mildly enlarged prostatic hyperplasia, Halo alone can achieve the desired therapeutic effect, thereby reducing the financial burden on patients and improving compliance with long-term medication.